Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

02/27/17ATHOS-3 Topline Results
09/08/16LJPC-401 Phase 1 Results and Development Update Presentation
09/08/16La Jolla Pharmaceutical LJPC-401 Phase 1 Results and Development Update

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $34.11 with a 52 week high of $39.26 and a 52 week low of $14.41.
Price$34.11
Change (%) Stock is Up 0.52 (1.55%)
Volume187,477
Data as of 03/22/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events




There are currently no events scheduled.

Recent News


La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock

03/20/17

SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2017-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla” or the “Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients s

Read More

La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501

02/27/17

-- Primary efficacy endpoint analysis highly statistically significant (p<0.00001) -- Trend toward longer survival observed -- New Drug Application planned for second half of 2017 -- Company to h

Read More

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress

02/23/17

SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2017-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts